Actionable news
0
All posts from Actionable news
Actionable news in GILD: Gilead Sciences, Inc.,

NASH: KOL Insight [2017]

LONDON, July 5, 2017 /PRNewswire/ -- Will novel therapies revolutionise the treatment of NASH?

No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but how is this set to change within the next five years? Allergan/Tobira's cenicriviroc and Gilead's selonsertib have entered the Phase III pipeline but how do they compare with other agents, Intercept's obeticholic acid and Genfit's elafibranor. How important are improvements in fibrosis and what do key opinion leaders (KOLs) believe will impact drug approval prospects? Experts discuss current study designs and endpoints and the challenges facing novel therapies such as long-term safety, cost and diagnosis.

Learn how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Nonalcoholic steatohepatitis (NASH). 6 US and 6 European KOLs give their insight on two off-label marketed products and 12 pipeline programmes. KOLs also provide their candid views on the potential for novel mechanisms of action.

Take a tour of the report now:

The table of contents >
The key business questions answered >
The key KOL quotes >
See the therapies covered >
Find out who the 6 EU & 6 US KOLs are >
Review an extract from the report - 1 drug profile >

Top Takeaways

Obeticholic acid approved for primary biliary cirrhosis (PBC) but what are its prospects in NASH? Find out how KOLs view the modifications of the pivotal Phase III REGENERATE study and whether they are concerned about long-term safety and cost?
Cenicriviroc and selonsertib have entered Phase III development but what are KOL expectations? Both drugs have demonstrated improvements in fibrosis in Phase II studies but what do the experts think about potential future outcomes?
Does elafibranor have potential for broad use in NASH? The Phase...


More